{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:31:51Z","timestamp":1784341911556,"version":"3.55.0"},"reference-count":58,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201700040I\/75N93019F00271"],"award-info":[{"award-number":["HHSN272201700040I\/75N93019F00271"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,7,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Inhalation anthrax is the most severe form of\n              <jats:italic>Bacillus anthracis<\/jats:italic>\n              infection, often progressing to fatal conditions if left untreated. While recommended antibiotics can effectively treat anthrax when promptly administered, strains engineered for antibiotic resistance could render these drugs ineffective. Telavancin, a semisynthetic lipoglycopeptide antibiotic, was evaluated in this study as a novel therapeutic against anthrax disease. Specifically, the aims were to (i) assess\n              <jats:italic>in vitro<\/jats:italic>\n              potency of telavancin against 17\n              <jats:italic>B. anthracis<\/jats:italic>\n              isolates by minimum inhibitory concentration (MIC) testing and (ii) evaluate protective efficacy in rabbits infected with a lethal dose of aerosolized anthrax spores and treated with human-equivalent intravenous telavancin doses (30 mg\/kg every 12 hours) for 5 days post-antigen detection versus a humanized dose of levofloxacin and vehicle control. Blood samples were collected at various times post-infection to assess the level of bacteremia and antibody production, and tissues were collected to determine bacterial load. The animals\u2019 body temperatures were also recorded. Telavancin demonstrated potent bactericidal activity against all strains tested (MICs 0.06\u20130.125 \u03bcg\/mL). Further, telavancin conveyed 100% survival in this model and cleared\n              <jats:italic>B. anthracis<\/jats:italic>\n              from the bloodstream and organ tissues more effectively than a humanized dose of levofloxacin. Collectively, the low MICs against all strains tested and rapid bactericidal\n              <jats:italic>in vivo<\/jats:italic>\n              activity demonstrate that telavancin has the potential to be an effective alternative for the treatment or prophylaxis of anthrax infection.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.00112-24","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T13:00:49Z","timestamp":1718715649000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["Rapid\n            <i>in vitro<\/i>\n            activity of telavancin against\n            <i>Bacillus anthracis<\/i>\n            and\n            <i>in vivo<\/i>\n            protection against inhalation anthrax infection in the rabbit model"],"prefix":"10.1128","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0167-8169","authenticated-orcid":false,"given":"William S.","family":"Lawrence","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Peel","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Slayden","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology &amp; Pathology, Colorado State University, Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny W.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace B.","family":"Baze","sequence":"additional","affiliation":[{"name":"Department of Comparative Medicine and Research, University of Texas MD Anderson, Bastrop, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8520-0279","authenticated-orcid":true,"given":"Martha E.","family":"Hensel","sequence":"additional","affiliation":[{"name":"Department of Comparative Medicine and Research, University of Texas MD Anderson, Bastrop, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elbert B.","family":"Whorton","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Texas Medical Branch, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-690X","authenticated-orcid":true,"given":"David W. C.","family":"Beasley","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Cummings","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology &amp; Pathology, Colorado State University, Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Macias-Perez","sequence":"additional","affiliation":[{"name":"Product Development Division, Cumberland Pharmaceuticals, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7333.336"},{"key":"e_1_3_4_3_2","unstructured":"U.S. Food and Drug Administration. 2018. Anthrax. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/anthrax#:~:text=The%20mortality%20rates%20from%20anthrax%20vary%2C%20depending%20on a%20fatality%20rate%20that%20is%2080%25%20or%20higher. Retrieved 25 Jan 2023."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-4-200602210-00009"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9050370"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2011.07.005"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7973702"},{"key":"e_1_3_4_8_2","first-page":"415","volume-title":"Medical aspects of chemical and biological warfare","author":"Eitzen E","year":"1997","unstructured":"Eitzen E, Takafuji E. 1997. Historical overview of biological warfare, p 415\u2013423. In Sidell F, Takafuji E, Franz D (ed), Medical aspects of chemical and biological warfare. Office of The Surgeon General at TMM Publications, Washington, DC."},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0810.020353"},{"key":"e_1_3_4_10_2","unstructured":"World Health Organization Geneva. 1969. Health and aspects of chemical and biological weapons. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/39444. Retrieved 25 Jan 2023."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2003.08.067"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.57.326"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01710-08"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/11534440-000000000-00000"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00742-09"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01641-07"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01737-09"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ534"},{"key":"e_1_3_4_21_2","unstructured":"Vibativ (telavancin) [package insert]. 2020. Cumberland Pharmaceuticals Inc. Nashville TN."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh156"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00100-07"},{"key":"e_1_3_4_24_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. 2023. Breakpoint tables for interpretation of MICs and zone diameters. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_13.0_Breakpoint_Tables.pdf. Retrieved 25 Jan 2023."},{"key":"e_1_3_4_25_2","volume-title":"46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Thornsberry C","year":"2006","unstructured":"Thornsberry C, Draghi D, Benton B, Cohen M, Jones M, Krause K, Sahm D. 2006. \u201cBaseline profile of telavancin activity against streptococci; results of the USA surveillance initiative\u201d 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA."},{"key":"e_1_3_4_26_2","volume-title":"45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Draghi D","year":"2005","unstructured":"Draghi D, Jones M, Flamm R, Thornsberry C, Sahm D. 2005. \u201cTelavancin activity against current and diverse populations of enterococci and Streptococcus pneumoniae\u201d 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC."},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2019.0104"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/2049936117690501"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl424"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki198"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2149-2152.2004"},{"key":"e_1_3_4_32_2","volume-title":"44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Kaniga K","year":"2004","unstructured":"Kaniga K, Blosser R, Karlowsky J, Sahm D. 2004. \u201cIn vitro activity of telavancin (TD-6424) against Bacillus anthracis\u201d 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC."},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.3109\/08958378.2016.1140850"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01376-15"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac028"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02434-16"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2006.26.1.3"},{"key":"e_1_3_4_38_2","first-page":"336","article-title":"On the histopathology of experimental anthrax in the guinea pig","volume":"36","author":"ROSS JM","year":"1955","unstructured":"ROSS JM. 1955. On the histopathology of experimental anthrax in the guinea pig. Br J Exp Pathol 36:336\u2013339.","journal-title":"Br J Exp Pathol"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1700730219"},{"key":"e_1_3_4_40_2","first-page":"982","article-title":"The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation","volume":"122","author":"Zaucha GM","year":"1998","unstructured":"Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med 122:982\u2013992.","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1354\/vp.44-5-716"},{"key":"e_1_3_4_42_2","first-page":"416","article-title":"Pathology of experimental respiratory anthrax in Macaca mulatta","volume":"44","author":"Gleiser CA","year":"1963","unstructured":"Gleiser CA, Berdjis CC, Hartman HA, Gochenour WS. 1963. Pathology of experimental respiratory anthrax in Macaca mulatta. Br J Exp Pathol 44:416\u2013426.","journal-title":"Br J Exp Pathol"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.lab.0000080599.43791.01"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl222"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3163-3165.2005"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01877-16"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260539"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1017\/s0022172400044272"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01050-06"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01875-06"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6804a1"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac567"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac536"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.770-773.2006"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00298-18"},{"key":"e_1_3_4_56_2","volume-title":"46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Sahm D","year":"2006","unstructured":"Sahm D, Benton B, Jones R, Krause K, Thornsberry C, Draghi D. 2006. \u201cInteraction of telavancin and other antimicrobial agents tested against key gram positive species\u201d 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA"},{"key":"e_1_3_4_57_2","unstructured":"National Institutes of Allergy and Infectious Diseases. 2019. In vitro assessment for antimicrobial activity program. Available from: https:\/\/www.niaid.nih.gov\/research\/vitro-assessment-antimicrobial-activity. Retrieved 25 Jan 2025."},{"key":"e_1_3_4_58_2","volume-title":"M45: methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. M45: methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. 3rd ed. Wayne, PA.","edition":"3"},{"key":"e_1_3_4_59_2","volume-title":"M100: performance standards for antimicrobial susceptibility testing","author":"CLSI","year":"2022","unstructured":"CLSI. 2022. M100: performance standards for antimicrobial susceptibility testing. 32nd ed. Wayne, PA.","edition":"32"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.195-201.2005"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00112-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00112-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T13:03:18Z","timestamp":1720530198000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00112-24"}},"subtitle":[],"editor":[{"given":"Helen","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,9]]}},"alternative-id":["10.1128\/aac.00112-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.00112-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"2024-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00112-24"}}